Cyclosporine: Difference between revisions
(contraindications) |
(adverse reactions) |
||
| Line 50: | Line 50: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*HTN, severe | |||
*immunosuppression | |||
*infection, severe | |||
*opportunistic infection | |||
*BK virus-associated nephropathy | |||
*hyperkalemia, severe | |||
*nephrotoxicity | |||
*hepatotoxicity | |||
*glomerular capillary thrombosis | |||
*diabetes mellitus | |||
*leukopenia | |||
*thrombocytopenia | |||
*hemolytic anemia | |||
*malignancy | |||
*malignancy | |||
*seizures | |||
*encephalopathy | |||
*posterior reversible encephalopathy syndrome | |||
*neurotoxicity | |||
*intracranial hypertension | |||
*optic disc edema | |||
*MI | |||
*depression | |||
*pancreatitis | |||
*GI bleeding | |||
===Common=== | ===Common=== | ||
Revision as of 02:19, 9 February 2016
Administration
- Type: immunosuppressant
- Dosage Forms: 25,100; 100/mL
- Routes of Administration: PO, injection
- Common Trade Names: Sandimmune
Adult Dosing
Organ transplant rejection prophylaxis
- Dosing protocols vary
- Start: 7-9 mg/kg/day PO divided BID; give 1st dose 4-12 hr pre-transplant or postop
- For heart, kidney, or liver transplant, adjust dose based on target levels, rejection status, adverse effects
Rheumatoid arthritis, severe
- Start: 2.5 mg/kg/day PO divided BID, increase 0.5-0.75 mg/kg/day after 8 wk and after 12 wk; Max: 4 mg/kg/day
- Use alone or with methotrexate; decreased 25-50% PRN adverse effects, discontinue if no benefit by 16 wks
Psoriasis, severe recalcitrant plaque
- Start: 2.5 mg/kg/day PO divided BID, increase 0.5 mg/kg/day q 2 wk after 4 wk; Max: 4 mg/kg/day
- Decrease 25-50% PRN adverse effects, discontinue if inadequate response after 6 weeks on max tolerated dose
Pediatric Dosing
Organ transplant rejection prophylaxis
- Dosing protocols vary
- Start 7-9 mg/kg/day PO divided BID, give 1st dose 4-12 hr pre-transplant or post op
- For heart, kidney, or liver transplant, adjust dose based on target levels, rejection status, adverse effects
Special Populations
- Pregnancy Rating: Pregnancy Category C
- Lactation risk: safety unknown
Renal Dosing
- Adult:
- transplant: no adjustment
- rheumatoid arthritis or psoriasis: contraindicated in renal impairment
- Pediatric:
- transplant: no adjustment
Hepatic Dosing
- Adult: not defined, caution advised
- Pediatric: not defined, caution advised
Contraindications
- Allergy to class/drug
- uncontrolled hypertension (RA or psoriasis use)
- renal impairment (RA or psoriasis use)
- malignancy (RA or psoriasis use)
- PUVA/UVB tx (psoriasis use)
- concurrent immunosuppressants (psoriasis use)
- coal tar tx (psoriasis use)
- concomitant XRT (psoriasis use)
Adverse Reactions
Serious
- HTN, severe
- immunosuppression
- infection, severe
- opportunistic infection
- BK virus-associated nephropathy
- hyperkalemia, severe
- nephrotoxicity
- hepatotoxicity
- glomerular capillary thrombosis
- diabetes mellitus
- leukopenia
- thrombocytopenia
- hemolytic anemia
- malignancy
- malignancy
- seizures
- encephalopathy
- posterior reversible encephalopathy syndrome
- neurotoxicity
- intracranial hypertension
- optic disc edema
- MI
- depression
- pancreatitis
- GI bleeding
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
